Adverse effects of the cancer therapy on osteoclast-mediated bone loss in patients with cancers: a challenge

It is well-known that cancer therapies, including chemotherapy drugs, aromatase inhibitors and gonadotropin-releasing homone analogues, commonly contribute to remarkably reduce the bone mineral density, subsequently increase rate of loss. For instance, in patients with prostate treated androgene deprivation therapy (ADT), or drugs such as doxorubicin cisplatin calcicum levels were significantly decreased body, thereby leading Besides, widely used treat breast cancer, antiresorptive agents targeting receptor activator nuclear factor кB ligand can also trigger Osteoclasts (OCs), derived from monocyte/macrophage lineage, are deifferentiated into mature, multinucleated OCs (a process known osteoclastogenesis) via a series osteoclastogenic signaling pathways, responsible for resorbing bone. This review article characterizes summarizes adverse effects on accelerating OC-induced defects increased resorption impaired density (BMD) cancers.